Archbold Vaccine Clinic

First, second and booster doses are available each Wednesday from 10am-6pm. The clinic is located in Williams Auditorium at Archbold Memorial Hospital. No appointment is required.

We are only administering the Pfizer booster shot to those that received Pfizer as their primary series at this time.

For more information regarding booster dose eligibility, click here.

For directions to the clinic, please click here.

To download the consent form ahead of time, click the button below.

If your organization/business is interested in scheduling an on-site vaccine clinic, please click the button below and fill out the form.

Vaccine Update (9/24/21)

The CDC now recommends that people aged 65 years and older, residents in long-term care settings, and people aged 50–64 years with underlying medical conditions should receive a booster shot of Pfizer-BioNTech’s COVID-19 Vaccine at least 6 months after completing their Pfizer-BioNTech primary series. Other groups may receive a booster shot based on their individual risk and benefit. Read CDC’s media statement.

For more information, please visit

COVID-19 Vaccine Information

The Pfizer COVID-19 Vaccine is currently available to people 12 years and older. The vaccines are our best option for fighting COVID-19 and we will work hard to administer vaccines to each member of our community that chooses to be vaccinated until the threat of COVID-19 is eliminated. The COVID-19 Vaccine is safe, well-researched, highly effective, and still available at no cost to you.

Since Archbold administered the first COVID-19 Vaccines in December 2020, nearly 30,000 doses have been given throughout the Archbold system.

Your friends, family, and neighbors are getting vaccinated.

The risk of COVID-19 and its variants are very much present in our community.

We can end the threat of this current surge and this pandemic in our community, but we need your help.

Choose to save lives. Choose to get vaccinated.

Please see below for more detailed information regarding the vaccines.

FDA Approval
  • According to the CDC, as of Monday, August 23, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.
  • FDA-approved vaccines undergo the agency’s standard process for reviewing the quality, safety and effectiveness of medical products. For all vaccines, the FDA evaluates data and information included in the manufacturer’s submission of a biologics license application (BLA). A BLA is a comprehensive document that is submitted to the agency providing very specific requirements. For Comirnaty, the BLA builds on the extensive data and information previously submitted that supported the EUA, such as preclinical and clinical data and information, as well as details of the manufacturing process, vaccine testing results to ensure vaccine quality and inspections of the sites where the vaccine is made. The agency conducts its own analyses of the information in the BLA to make sure the vaccine is safe and effective and meets the FDA’s standards for approval.
  • For more information regarding the FDA’s approval, please click here.
Emergency Use Authorizations (EUAs)
  • The issuance of a EUA is different than an FDA approval (licensure) of a vaccine. In determining whether to issue a EUA for a product, the FDA evaluates the available evidence and assesses any known or potential risks and any known or potential benefits, and if the benefit-risk assessment is favorable, the product is made available during the emergency.
  • For more information about the COVID-19 EUAs, please click here.
What are messenger RNA (mRNA) vaccines?
  • mRNA vaccines carry genetic material that teaches our cells how to make a harmless piece of “spike protein,” which is found on the surface of the SARS-CoV-2 virus.
    • Genetic material from the vaccine is destroyed by our cells once copies of the spike protein are made and it is no longer needed.
  • Cells display this piece of spike protein on their surface, and an immune response is triggered inside our bodies. This produces antibodies to protect us from getting infected if the SARS-CoV-2 virus enters our bodies.
Specific COVID-19 mRNA Vaccine
  • These mRNA vaccines are expected to produce side effects after vaccination, especially after the 2nd dose. Possible side effects may include:
    • Fever
    • Headache
    • Muscle aches
  • No significant safety concerns were identified in the clinical trials. COVID-19 vaccines were tested in large clinical trials to make sure they meet safety standards. Many people were recruited to participate in these trials to see how the vaccines offer protection to people of different ages, races, and ethnicities, as well as those with different medical conditions.
  • The mRNA COVID-19 vaccine cannot give you COVID-19 and does not contain live or killed viral particles.
  • For more information regarding mRNA vaccines, please click here.
Storage and Distribution
  • Archbold has the capacity to store the COVID vaccines in an ultra-cold freezer and has a distribution plan in place in order to keep the vaccine at the correct temperature while administering.
Taking Precautions
  • Even when people receive the vaccine they will not be immediately protected and will need to continue to wear masks, social distance, and practice frequent hand hygiene.
  • The Pfizer and Moderna vaccines will require 2 shots, with a few weeks between each shot, and protection will usually occur about 2 weeks after the second shot.
  • Even when you receive your vaccine, most people around you may have not. It is still possible to transmit the disease to others until the vaccine is widely used. Wearing a mask, social distancing, and practicing hand hygiene protects those who have not been vaccinated, especially residents in long-term care facilities.
  • It is safe to get the vaccine even if you have had COVID-19 and have antibodies. The additional protection will not cause harm and can increase your protection from future COVID-19 infections.
  • For frequently asked questions, please click here.

For more information about the vaccine, please visit the CDC website.